TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03808922: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Sponsor: Ansun Biopharma, Inc. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 274 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT03808922 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03808922 Rescue Dossier →